Risankizumab, an Interleukin-23 Inhibitor, for Moderate-Severe Crohn’s Disease: Advancing Care Beyond Anti-TNF Therapy
Released Wednesday, 25th January 2023
Good episode? Give it some love!
Risankizumab, an Interleukin-23 Inhibitor, for Moderate-Severe Crohn’s Disease: Advancing Care Beyond Anti-TNF Therapy
Risankizumab, an Interleukin-23 Inhibitor, for Moderate-Severe Crohn’s Disease: Advancing Care Beyond Anti-TNF Therapy
Wednesday, 25th January 2023
Good episode? Give it some love!
Rate Episode
Rate
From The Podcast
Evidence-Based GI: An ACG Publication and Podcast
A new monthly publication from the American College of Gastroenterology, Evidence-Based GI (EBGI) uses evidence-based methods to create abstracts and explain study results of new and important articles in the field of gastroenterology and hepatology. Listen as editors of EBGI discuss the articles they review and how the recommendations can be applied to your practice.Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Episode Tags
Do you host or manage this podcast?
Claim and edit this page to your liking.
,Claim and edit this page to your liking.
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us